Clinical Scorecard: Outcomes and Implications of Negative Multiparametric Magnetic Resonance Imaging in Prostate Cancer Detection

At a Glance

Key Highlights

• EAU guidelines recommend mpMRI prior to prostate biopsy to improve detection rates.
• Negative mpMRI (PI-RADS ≤ 2) does not exclude prostate cancer; 20.7% of biopsied patients had PCa, 6.7% had clinically significant PCa (ISUP ≥ 2).
• Age was an independent predictor for undergoing biopsy after negative mpMRI; PSA and PSA density were not predictive.

Guideline-Based Recommendations

Diagnosis

• Perform multiparametric MRI prior to prostate biopsy as per EAU guidelines.
• Consider systematic 12-fold biopsy in patients with negative mpMRI but clinical suspicion of prostate cancer.
• Use PI-RADS classification to interpret mpMRI results; negative defined as PI-RADS ≤ 2.

Management

• Systematic biopsies remain standard in negative mpMRI patients with suspicion for PCa due to risk of undetected cancer.
• Saturation biopsies (24-fold) may be considered if initial biopsy and follow-up mpMRI remain negative.
• MRI/TRUS fusion targeted biopsy is indicated if suspicious lesions appear on follow-up mpMRI.

Monitoring & Follow-up

• Follow-up mpMRI and PSA monitoring are important in patients with negative initial mpMRI and ongoing clinical suspicion.
• Monitor PSA levels, but PSA, free PSA, and PSA density alone are insufficient to guide biopsy decisions in negative mpMRI cases.

Risks

• Risk of overdiagnosis and overtreatment of non-clinically significant prostate cancer exists with systematic biopsy after negative mpMRI.
• Unnecessary biopsies may occur due to patient and clinician desire for diagnostic clarification despite negative imaging.

Patient & Prescribing Data

Men with negative mpMRI and clinical suspicion of prostate cancer undergoing biopsy or surveillance

Approximately 20.7% of biopsied patients had prostate cancer detected despite negative mpMRI; 6.7% had clinically significant cancer requiring treatment.

Clinical Best Practices

• Use mpMRI with standardized PI-RADS assessment prior to biopsy to improve detection accuracy.
• Consider patient age and clinical context when deciding on biopsy after negative mpMRI.
• Systematic biopsy remains necessary in negative mpMRI patients due to risk of missed clinically significant cancer.
• Further research is needed on prognostic biomarkers and parameters to refine biopsy decisions in negative mpMRI cases.

References

• EAU Guidelines on Prostate Cancer